ReviewJournal of cellular and molecular medicine2026
Targeting STAT3 to Modulate the Effectiveness of Cardioprotective Conditioning Strategies Against Myocardial Ischemia-Reperfusion Injury in Subjects With Diabetic Cardiomyopathy.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a major cause of cardiovascular morbidity and mortality. Reperfusion, although essential for myocardial restoration, can paradoxically exacerbate injury through oxidative stress, calcium overload, mitochondrial permeability transition pore opening and inflammatory infiltration. The vulnerability to MIRI is substantially amplified in subjects with diabetes mellitus, where chronic hyperglycemia, insulin resistance, and the resulting oxidative stress and low-grade inflammation impair endogenous cardioprotective mechanisms and worsen postinfarction outcomes. Ischemic conditioning strategies, including preconditioning and postconditioning, serve as powerful innate methods to mitigate MIRI by exposing the myocardium to brief, sublethal ischemic episodes that activate crucial prosurvival signalling pathways. Among these pathways, the survivor activating factor enhancement pathway, which is mediated predominantly by signal transducer and activator of transcription 3 (STAT3), and the reperfusion injury salvage kinase pathway, which involves AKT and ERK, are particularly important. However, in many models of diabetes, diabetes-induced STAT3 dysfunction may disrupt these protective pathways, often making conditioning stimuli less effective. The precise mechanisms underlying this impairment remain incompletely understood. Additionally, paradoxical changes in STAT3 expression have been reported, and key posttranslational modifications of STAT3 have not yet been investigated in the context of diabetic MIRI. This review provides a critical appraisal of the role, regulatory mechanisms and therapeutic potential of STAT3 in ischemic conditioning in patients with diabetes and discusses strategies aimed at restoring cardioprotection in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.